Phosphodiesterase Type 5 Inhibition Is a Novel Therapeutic Option in Raynaud Disease | Zendy

Evren Caglayan | Zendy; Michael Huntgeburth | Zendy; Thomas Karasch | Zendy; Julia Weihrauch | Zendy; Nicolas Hunzelmann | Zendy; Thomas Krieg | Zendy; Erland Erdmann | Zendy; Stephan Rosenkranz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phosphodiesterase Type 5 Inhibition Is a Novel Therapeutic Option in Raynaud Disease

Author(s) -

Evren Caglayan,

Michael Huntgeburth,

Thomas Karasch,

Julia Weihrauch,

Nicolas Hunzelmann,

Thomas Krieg,

Erland Erdmann,

Stephan Rosenkranz

Publication year - 2006

Publication title -

archives of internal medicine

Language(s) - English

Resource type - Journals

eISSN - 1538-3679

pISSN - 0003-9926

DOI - 10.1001/archinte.166.2.231

Subject(s) - vardenafil , medicine , cgmp specific phosphodiesterase type 5 , connective tissue disease , connective tissue , sildenafil , population , laser doppler velocimetry , blood flow , gastroenterology , surgery , disease , tadalafil , pathology , autoimmune disease , environmental health

Raynaud disease (RD) is a common disorder affecting 3% to 5% of the healthy population, and occurs in more than 90% of patients with connective tissue diseases. The therapeutic options remain limited, particularly in patients with secondary RD due to connective tissue disease. Theoretical considerations lead to the expectation that phosphodiesterase type 5 inhibitors may improve clinical symptoms and digital blood flow in patients with RD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research